Top-line results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2021.
Title: A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer.
Nishimura M, et al. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. Gastrointest Endosc. 87:1126-1131, 2018.